Rexinoids as therapeutics for Alzheimer disease: Role of APOE

Current Topics in Medicinal Chemistry

Volumn 16, Issue 30, 2016, Pages 708-720

  Koster, Kevin P ^a   Smith, Conor ^a   Valencia Olvera, Ana C ^a   Thatcher, Gregory R J ^b   LaDu, Mary Jo ^a   Tai, Leon M ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

ABCA1; Alzheimer s disease; Amyloid; Apolipoprotein E; A peptide; Bexarotene; Rexinoids; Therapeutic

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BEXAROTENE; RETINOID X RECEPTOR; REXINOID; UNCLASSIFIED DRUG; ABC TRANSPORTER A1; APOLIPOPROTEIN E; RETINOID;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL (TOPIC); COGNITION; DRUG REPOSITIONING; GENE EXPRESSION; GENETIC RISK; HEPATOMEGALY; HUMAN; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN PHOSPHORYLATION; GAIN OF FUNCTION MUTATION; LOSS OF FUNCTION MUTATION; MOUSE; PROTEIN DEPLETION; PROTEIN FUNCTION; REVIEW; TRANSGENIC MOUSE; METABOLISM;

ALZHEIMER DISEASE; APOLIPOPROTEINS E; HUMANS; RETINOIDS;

EID: 85011012880     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026616666160617090227     Document Type: Article

References (165)

1. 2015 Alzheimer’s disease facts and figures. Alzheimers Dement, 2015, 11, (3), 332-384.
2. Reiman, E.M.; McKhann, G.M.; Albert, M.S.; Sperling, R.A.; Petersen, R.C.; Blacker, D., Clinical impact of updated diagnostic and research criteria for Alzheimer’s disease. J Clin Psychiatry, 2011, 72, (12), e37.
3. Arrighi, H.M.; Neumann, P.J.; Lieberburg, I.M.; Townsend, R.J., Lethality of Alzheimer disease and its impact on nursing home placement. Alzheimer Dis Assoc Disord, 2010, 24, (1), 90-95.
4. Tejada-Vera, B., Mortality from Alzheimer’s disease in the United States: data for 2000 and 2010. NCHS Data Brief, 2013, (116), 1-8.
5. Ganguli, M.; Dodge, H.H.; Shen, C.; Pandav, R.S.; DeKosky, S.T., Alzheimer disease and mortality: a 15-year epidemiological study. Arch Neurol, 2005, 62, (5), 779-784.
6. Waring, S.C.; Doody, R.S.; Pavlik, V.N.; Massman, P.J.; Chan, W., Survival among patients with dementia from a large multi-ethnic population. Alzheimer Dis Assoc Disord, 2005, 19, (4), 178-183.
7. Brookmeyer, R.; Corrada, M.M.; Curriero, F.C.; Kawas, C., Survival following a diagnosis of Alzheimer disease. Arch Neurol, 2002, 59, (11), 1764-1767.
8. Droogsma, E.; van Asselt, D.; van Steijn, J.; Diekhuis, M.; Veeger, N.; De Deyn, P.P., Long-term Course of Alzheimer Disease in Patients Treated According to the Dutch Dementia Guideline at a Memory Clinic: A “Real-Life” Study. Alzheimer Dis Assoc Disord, 2015.
9. Gillette-Guyonnet, S.; Andrieu, S.; Nourhashemi, F.; Gardette, V.; Coley, N.; Cantet, C.; Gauthier, S.; Ousset, P.J.; Vellas, B.; Group, R.F.S., Long-term progression of Alzheimer’s disease in patients under antidementia drugs. Alzheimers Dement, 2011, 7, (6), 579-592.
10. Habermann, S.; Cooper, C.; Katona, C.; Livingston, G., Predictors of entering 24-h care for people with Alzheimer’s disease: results from the LASER-AD study. Int J Geriatr Psychiatry, 2009, 24, (11), 1291-1298.
11. Hardy, J., The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal. J Neurochem, 2009, 110, (4), 1129-1134.
12. Wisniewski, T.; Sigurdsson, E.M., Murine models of Alzheimer’s disease and their use in developing immunotherapies. Biochim Biophys Acta, 2010, 1802, (10), 847-859.
13. Takeda, M.; Martinez, R.; Kudo, T.; Tanaka, T.; Okochi, M.; Tagami, S.; Morihara, T.; Hashimoto, R.; Cacabelos, R., Apolipoprotein E and central nervous system disorders: reviews of clinical findings. Psychiatry Clin Neurosci, 2010, 64, (6), 592-607.
14. Wiseman, F.K.; Al-Janabi, T.; Hardy, J.; Karmiloff-Smith, A.; Nizetic, D.; Tybulewicz, V.L.; Fisher, E.M.; Strydom, A., A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci, 2015, 16, (9), 564-574.
15. McCarron, M.; McCallion, P.; Reilly, E.; Mulryan, N., A prospective 14-year longitudinal follow-up of dementia in persons with Down syndrome. J Intellect Disabil Res, 2014, 58, (1), 61-70.
16. Zigman, W.B.; Schupf, N.; Urv, T.; Zigman, A.; Silverman, W., Incidence and temporal patterns of adaptive behavior change in adults with mental retardation. Am J Ment Retard, 2002, 107, (3), 161-174.
17. Manelli, A.M.; Bulfinch, L.C.; Sullivan, P.M.; LaDu, M.J., Abeta42 neurotoxicity in primary co-cultures: effect of apoE isoform and Abeta conformation. Neurobiol Aging, 2007, 28, (8), 1139-1147.
18. Shin, M.K.; Kim, H.G.; Kim, K.L., A novel brain-derived neurotrophic factor-modulating peptide attenuates Abeta1-42-induced neurotoxicity in vitro. Neurosci Lett, 2015, 595, 63-68.
19. Lambert, M.P.; Barlow, A.K.; Chromy, B.A.; Edwards, C.; Freed, R.; Liosatos, M.; Morgan, T.E.; Rozovsky, I.; Trommer, B.; Viola, K.L.; Wals, P.; Zhang, C.; Finch, C.E.; Krafft, G.A.; Klein, W.L., Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A, 1998, 95, (11), 6448-6453.
20. Klein, W.L.; Krafft, G.A.; Finch, C.E., Targeting small Abeta oligomers: the solution to an Alzheimer’s disease conundrum? Trends Neurosci, 2001, 24, (4), 219-224.
21. Hardy, J.; Selkoe, D.J., The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science, 2002, 297, (5580), 353-356.
22. Selkoe, D.J., Deciphering the genesis and fate of amyloid betaprotein yields novel therapies for Alzheimer disease. J Clin Invest, 2002, 110, (10), 1375-1381.
23. Sperling, R.; Mormino, E.; Johnson, K., The evolution of preclinical Alzheimer’s disease: implications for prevention trials. Neuron, 2014, 84, (3), 608-622.
24. Stella, F.; Radanovic, M.; Canineu, P.R.; de Paula, V.J.; Forlenza, O.V., Anti-dementia medications: current prescriptions in clinical practice and new agents in progress. Ther Adv Drug Saf, 2015, 6, (4), 151-165.
25. O’Brien, J.T.; Burns, A.; Group, B.A.P.D.C., Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol, 2011, 25, (8), 997-1019.
26. Cummings, J.L.; Morstorf, T.; Zhong, K., Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther, 2014, 6, (4), 37.
27. Verghese, P.B.; Castellano, J.M.; Holtzman, D.M., Apolipoprotein E in Alzheimer’s disease and other neurological disorders. Lancet Neurol, 2011, 10, (3), 241-252.
28. Reitz, C.; Mayeux, R., Use of genetic variation as biomarkers for mild cognitive impairment and progression of mild cognitive impairment to dementia. J Alzheimers Dis, 2010, 19, (1), 229-251.
29. Leoni, V., The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer’s disease. Clin Chem Lab Med, 2011, 49, (3), 375-383.
30. Corder, E.H.; Saunders, A.M.; Strittmatter, W.J.; Schmechel, D.E.; Gaskell, P.C.; Small, G.W.; Roses, A.D.; Haines, J.L.; Pericak-Vance, M.A., Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science, 1993, 261, (5123), 921-923.
31. Khachaturian, A.S.; Corcoran, C.D.; Mayer, L.S.; Zandi, P.P.; Breitner, J.C., Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study. Arch Gen Psychiatry, 2004, 61, (5), 518-524.
32. Saunders, A.M.; Strittmatter, W.J.; Schmechel, D.; George-Hyslop, P.H.; Pericak-Vance, M.A.; Joo, S.H.; Rosi, B.L.; Gusella, J.F.; Crapper-MacLachlan, D.R.; Alberts, M.J.; et al., Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology, 1993, 43, (8), 1467-1472.
33. Breitner, J.C.; Jarvik, G.P.; Plassman, B.L.; Saunders, A.M.; Welsh, K.A., Risk of Alzheimer disease with the epsilon4 allele for apolipoprotein E in a population-based study of men aged 62-73 years. Alzheimer Dis Assoc Disord, 1998, 12, (1), 40-44.
34. Farrer, L.A.; Cupples, L.A.; Haines, J.L.; Hyman, B.; Kukull, W.A.; Mayeux, R.; Myers, R.H.; Pericak-Vance, M.A.; Risch, N.; van Duijn, C.M., Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA, 1997, 278, (16), 1349-1356.
35. Cosentino, S.; Scarmeas, N.; Helzner, E.; Glymour, M.M.; Brandt, J.; Albert, M.; Blacker, D.; Stern, Y., APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology, 2008, 70, (19 Pt 2), 1842-1849.
36. Carrasquillo, M.M.; Crook, J.E.; Pedraza, O.; Thomas, C.S.; Pankratz, V.S.; Allen, M.; Nguyen, T.; Malphrus, K.G.; Ma, L.; Bisceglio, G.D.; Roberts, R.O.; Lucas, J.A.; Smith, G.E.; Ivnik, R.J.; Machulda, M.M.; Graff-Radford, N.R.; Petersen, R.C.; Younkin, S.G.; Ertekin-Taner, N., Late-onset Alzheimer’s risk variants in memory decline, incident mild cognitive impairment, and Alzheimer’s disease. Neurobiol Aging, 2014.
37. Mahley, R.W.; Rall, S.C., Jr., Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet, 2000, 1, 507-537.
38. LaDu, M.J.; Gilligan, S.M.; Lukens, J.R.; Cabana, V.G.; Reardon, C.A.; Van Eldik, L.J.; Holtzman, D.M., Nascent astrocyte particles differ from lipoproteins in CSF. J Neurochem, 1998, 70, (5), 2070-2081.
39. Michikawa, M.; Fan, Q.W.; Isobe, I.; Yanagisawa, K., Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem, 2000, 74, (3), 1008-1016.
40. Vance, J.E.; Hayashi, H., Formation and function of apolipoprotein E-containing lipoproteins in the nervous system. Biochim Biophys Acta, 2010, 1801, (8), 806-818.
41. LaDu, M.J.; Reardon, C.; Van Eldik, L.; Fagan, A.M.; Bu, G.; Holtzman, D.; Getz, G.S., Lipoproteins in the central nervous system. Ann N Y Acad Sci, 2000, 903, 167-175.
42. Zhu, Y.; Nwabuisi-Heath, E.; Dumanis, S.B.; Tai, L.M.; Yu, C.; Rebeck, G.W.; LaDu, M.J., APOE genotype alters glial activation and loss of synaptic markers in mice. Glia, 2012, 60, (4), 559-569.
43. Gale, S.C.; Gao, L.; Mikacenic, C.; Coyle, S.M.; Rafaels, N.; Murray Dudenkov, T.; Madenspacher, J.H.; Draper, D.W.; Ge, W.; Aloor, J.J.; Azzam, K.M.; Lai, L.; Blackshear, P.J.; Calvano, S.E.; Barnes, K.C.; Lowry, S.F.; Corbett, S.; Wurfel, M.M.; Fessler, M.B., APOepsilon4 is associated with enhanced in vivo innate immune responses in human subjects. J Allergy Clin Immunol, 2014, 134, (1), 127-134.
44. Tai, L.M.; Ghura, S.; Koster, K.P.; Liakaite, V.; Maienschein-Cline, M.; Kanabar, P.; Collins, N.; Ben-Aissa, M.; Lei, A.Z.; Bahroos, N.; Green, S.; Hendrickson, B.; Eldik, L.J.; LaDu, M.J., APOE-modulated Abeta-induced neuroinflammation in Alzheimer’s disease: current landscape, novel data and future perspective. J Neurochem, 2015.
45. Keene, C.D.; Cudaback, E.; Li, X.; Montine, K.S.; Montine, T.J., Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer’s disease. Curr Opin Neurobiol, 2011, 21, (6), 920-928.
46. Casey, C.S.; Atagi, Y.; Yamazaki, Y.; Shinohara, M.; Tachibana, M.; Fu, Y.; Bu, G.; Kanekiyo, T., Apolipoprotein E inhibits cerebrovascular pericyte mobility through a RhoA-mediated pathway. J Biol Chem, 2015.
47. Alata, W.; Ye, Y.; St-Amour, I.; Vandal, M.; Calon, F., Human apolipoprotein E varepsilon4 expression impairs cerebral vascularization and blood-brain barrier function in mice. J Cereb Blood Flow Metab, 2015, 35, (1), 86-94.
48. Zheng, M.; Wei, J.; Tang, Y.; Yang, C.; Wei, Y.; Yin, X.; Liu, Q., ApoE-deficient promotes blood-brain barrier disruption in experimental autoimmune encephalomyelitis via alteration of MMP-9. J Mol Neurosci, 2014, 54, (2), 282-290.
49. Halliday, M.R.; Rege, S.V.; Ma, Q.; Zhao, Z.; Miller, C.A.; Winkler, E.A.; Zlokovic, B.V., Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer’s disease. J Cereb Blood Flow Metab, 2015.
50. Halliday, M.R.; Pomara, N.; Sagare, A.P.; Mack, W.J.; Frangione, B.; Zlokovic, B.V., Relationship between cyclophilin a levels and matrix metalloproteinase 9 activity in cerebrospinal fluid of cognitively normal apolipoprotein e4 carriers and blood-brain barrier breakdown. JAMA Neurol, 2013, 70, (9), 1198-1200.
51. Qiu, W.Q.; Mwamburi, M.; Besser, L.M.; Zhu, H.; Li, H.; Wallack, M.; Phillips, L.; Qiao, L.; Budson, A.E.; Stern, R.; Kowall, N., Angiotensin converting enzyme inhibitors and the reduced risk of Alzheimer’s disease in the absence of apolipoprotein E4 allele. J Alzheimers Dis, 2013, 37, (2), 421-428.
52. Sperling, R.; Salloway, S.; Brooks, D.J.; Tampieri, D.; Barakos, J.; Fox, N.C.; Raskind, M.; Sabbagh, M.; Honig, L.S.; Porsteinsson, A.P.; Lieberburg, I.; Arrighi, H.M.; Morris, K.A.; Lu, Y.; Liu, E.; Gregg, K.M.; Brashear, H.R.; Kinney, G.G.; Black, R.; Grundman, M., Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol, 2012, 11, (3), 241-249.
53. Farlow, M.R.; Lahiri, D.K.; Poirier, J.; Davignon, J.; Schneider, L.; Hui, S.L., Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer’s disease. Neurology, 1998, 50, (3), 669-677.
54. Risner, M.E.; Saunders, A.M.; Altman, J.F.; Ormandy, G.C.; Craft, S.; Foley, I.M.; Zvartau-Hind, M.E.; Hosford, D.A.; Roses, A.D., Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. The pharmacogenomics journal, 2006, 6, (4), 246-254.
55. Mak, A.C.; Pullinger, C.R.; Tang, L.F.; Wong, J.S.; Deo, R.C.; Schwarz, J.M.; Gugliucci, A.; Movsesyan, I.; Ishida, B.Y.; Chu, C.; Poon, A.; Kim, P.; Stock, E.O.; Schaefer, E.J.; Asztalos, B.F.; Castellano, J.M.; Wyss-Coray, T.; Duncan, J.L.; Miller, B.L.; Kane, J.P.; Kwok, P.Y.; Malloy, M.J., Effects of the Absence of Apolipoprotein E on Lipoproteins, Neurocognitive Function, and Retinal Function. JAMA Neurol, 2014.
56. Cullum, C.M.; Weiner, M.F., Apolipoprotein E and neurocognitive function. JAMA Neurol, 2015, 72, (4), 478.
57. Laskowitz, D.T.; Kernagis, D.N., Congenital absence of apolipoprotein E and neurological function. JAMA Neurol, 2014, 71, (12), 1578-1579.
58. Lane-Donovan, C.; Herz, J., Is apolipoprotein e required for cognitive function in humans?: implications for Alzheimer drug development. JAMA Neurol, 2014, 71, (10), 1213-1215.
59. Zhang, S.H.; Reddick, R.L.; Piedrahita, J.A.; Maeda, N., Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science (New York, N.Y, 1992, 258, (5081), 468-471.
60. Zepa, L.; Frenkel, M.; Belinson, H.; Kariv-Inbal, Z.; Kayed, R.; Masliah, E.; Michaelson, D.M., ApoE4-Driven Accumulation of Intraneuronal Oligomerized Abeta42 following Activation of the Amyloid Cascade In Vivo Is Mediated by a Gain of Function. Int J Alzheimers Dis, 2011, 2011, 792070.
61. Trommer, B.L.; Shah, C.; Yun, S.H.; Gamkrelidze, G.; Pasternak, E.S.; Stine, W.B.; Manelli, A.; Sullivan, P.; Pasternak, J.F.; LaDu, M.J., ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42. Neurobiology of disease, 2005, 18, (1), 75-82.
62. Andrews-Zwilling, Y.; Bien-Ly, N.; Xu, Q.; Li, G.; Bernardo, A.; Yoon, S.Y.; Zwilling, D.; Yan, T.X.; Chen, L.; Huang, Y., Apolipoprotein E4 causes age-and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. J Neurosci, 2010, 30, (41), 13707-13717.
63. Bien-Ly, N.; Andrews-Zwilling, Y.; Xu, Q.; Bernardo, A.; Wang, C.; Huang, Y., C-terminal-truncated apolipoprotein (apo) E4 inefficiently clears amyloid-{beta} (A{beta}) and acts in concert with A{beta} to elicit neuronal and behavioral deficits in mice. Proc Natl Acad Sci U S A, 2011, 108, (10), 4236-4241.
64. Nathan, B.P.; Jiang, Y.; Wong, G.K.; Shen, F.; Brewer, G.J.; Struble, R.G., Apolipoprotein E4 inhibits, and apolipoprotein E3 promotes neurite outgrowth in cultured adult mouse cortical neurons through the low-density lipoprotein receptor-related protein. Brain Res, 2002, 928, (1-2), 96-105.
65. Bour, A.; Grootendorst, J.; Vogel, E.; Kelche, C.; Dodart, J.C.; Bales, K.; Moreau, P.H.; Sullivan, P.M.; Mathis, C., Middle-aged human apoE4 targeted-replacement mice show retention deficits on a wide range of spatial memory tasks. Behav Brain Res, 2008, 193, (2), 174-182.
66. Grootendorst, J.; Bour, A.; Vogel, E.; Kelche, C.; Sullivan, P.M.; Dodart, J.C.; Bales, K.; Mathis, C., Human apoE targeted replacement mouse lines: h-apoE4 and h-apoE3 mice differ on spatial memory performance and avoidance behavior. Behavioural Brain Research, 2005, 159, (1), 1-14.
67. Trommer, B.L.; Shah, C.; Yun, S.H.; Gamkrelidze, G.; Pasternak, E.S.; Ye, G.L.; Sotak, M.; Sullivan, P.M.; Pasternak, J.F.; LaDu, M.J., ApoE isoform affects LTP in human targeted replacement mice. Neuroreport, 2004, 15, (17), 2655-2658.
68. Bales, K.R.; Verina, T.; Cummins, D.J.; Du, Y.; Dodel, R.C.; Saura, J.; Fishman, C.E.; DeLong, C.A.; Piccardo, P.; Petegnief, V.; Ghetti, B.; Paul, S.M., Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A, 1999, 96, (26), 15233-15238.
69. Youmans, K.L.; Tai, L.M.; Nwabuisi-Heath, E.; Jungbauer, L.; Kanekiyo, T.; Gan, M.; Kim, J.; Eimer, W.A.; Estus, S.; Rebeck, G.W.; Weeber, E.J.; Bu, G.; Yu, C.; Ladu, M.J., APOE4-specific Changes in Abeta Accumulation in a New Transgenic Mouse Model of Alzheimer Disease. J Biol Chem, 2012, 287, (50), 41774-41786.
70. Tai, L.M.; Youmans, K.L.; Jungbauer, L.; Yu, C.; Ladu, M.J., Introducing Human APOE into Abeta Transgenic Mouse Models. Int J Alzheimers Dis, 2011, 2011, 810981.
71. Bell, R.D.; Winkler, E.A.; Singh, I.; Sagare, A.P.; Deane, R.; Wu, Z.; Holtzman, D.M.; Betsholtz, C.; Armulik, A.; Sallstrom, J.; Berk, B.C.; Zlokovic, B.V., Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature, 2012, 485, (7399), 512-516.
72. Bachmeier, C.; Paris, D.; Beaulieu-Abdelahad, D.; Mouzon, B.; Mullan, M.; Crawford, F., A multifaceted role for apoE in the clearance of beta-amyloid across the blood-brain barrier. Neurodegener Dis, 2013, 11, (1), 13-21.
73. Tai, L.M.; Koster, K.P.; Luo, J.; Lee, S.H.; Wang, Y.T.; Collins, N.C.; Ben Aissa, M.; Thatcher, G.R.; LaDu, M.J., Amyloid-beta Pathology and APOE Genotype Modulate Retinoid X Receptor Agonist Activity in Vivo. J Biol Chem, 2014, 289, (44), 30538-30555.
74. Bales, K.R.; Liu, F.; Wu, S.; Lin, S.; Koger, D.; DeLong, C.; Hansen, J.C.; Sullivan, P.M.; Paul, S.M., Human APOE isoformdependent effects on brain beta-amyloid levels in PDAPP transgenic mice. The Journal of neuroscience, 2009, 29, (21), 6771-6779.
75. Liu, D.S.; Pan, X.D.; Zhang, J.; Shen, H.; Collins, N.C.; Cole, A.M.; Koster, K.P.; Ben Aissa, M.; Dai, X.M.; Zhou, M.; Tai, L.M.; Zhu, Y.G.; LaDu, M.; Chen, X.C., APOE4 enhances agedependent decline in cognitive function by down-regulating an NMDA receptor pathway in EFAD-Tg mice. Mol Neurodegener, 2015, 10, (1), 7.
76. Michaelson, D.M., APOE epsilon4: The most prevalent yet understudied risk factor for Alzheimer’s disease. Alzheimers Dement, 2014, 10, (6), 861-868.
77. Dong, L.M.; Wilson, C.; Wardell, M.R.; Simmons, T.; Mahley, R.W.; Weisgraber, K.H.; Agard, D.A., Human apolipoprotein E: Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J. Biol. Chem., 1994, 269, (35), 22358-22365.
78. Dong, L.M.; Weisgraber, K.H., Human apolipoprotein E4 domain interaction: Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J. Biol. Chem., 1996, 271, (32), 19053-19057.
79. Weisgraber, K.H., Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112. J Lipid Res, 1990, 31, (8), 1503-1511.
80. Yu, C.; Youmans, K.L.; LaDu, M.J., Proposed mechanism for lipoprotein remodelling in the brain. Biochim Biophys Acta, 2010, 1801, (8), 819-823.
81. Ulrich, J.D.; Burchett, J.M.; Restivo, J.L.; Schuler, D.R.; Verghese, P.B.; Mahan, T.E.; Landreth, G.E.; Castellano, J.M.; Jiang, H.; Cirrito, J.R.; Holtzman, D.M., In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Mol Neurodegener, 2013, 8, 13.
82. Boehm-Cagan, A.; Michaelson, D.M., Reversal of apoE4-Driven Brain Pathology and Behavioral Deficits by Bexarotene. J Neurosci, 2014, 34, (21), 7293-7301.
83. Tai, L.M.; Mehra, S.; Shete, V.; Estus, S.; Rebeck, G.W.; Bu, G.; Ladu, M.J., Soluble apoE/Abeta complex: mechanism and therapeutic target for APOE4-induced AD risk. Mol Neurodegener, 2014, 9, (1), 2.
84. Chen, H.K.; Liu, Z.; Meyer-Franke, A.; Brodbeck, J.; Miranda, R.D.; McGuire, J.G.; Pleiss, M.A.; Ji, Z.S.; Balestra, M.E.; Walker, D.W.; Xu, Q.; Jeong, D.E.; Budamagunta, M.S.; Voss, J.C.; Freedman, S.B.; Weisgraber, K.H.; Huang, Y.; Mahley, R.W., Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons. J Biol Chem, 2012, 287, (8), 5253-5266.
85. Brodbeck, J.; McGuire, J.; Liu, Z.; Meyer-Franke, A.; Balestra, M.E.; Jeong, D.E.; Pleiss, M.; McComas, C.; Hess, F.; Witter, D.; Peterson, S.; Childers, M.; Goulet, M.; Liverton, N.; Hargreaves, R.; Freedman, S.; Weisgraber, K.H.; Mahley, R.W.; Huang, Y., Structure-dependent impairment of intracellular apolipoprotein E4 trafficking and its detrimental effects are rescued by smallmolecule structure correctors. J Biol Chem, 2011, 286, (19), 17217-17226.
86. Kim, J.; Eltorai, A.E.; Jiang, H.; Liao, F.; Verghese, P.B.; Kim, J.; Stewart, F.R.; Basak, J.M.; Holtzman, D.M., Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Abeta amyloidosis. J Exp Med, 2012, 209, (12), 2149-2156.
87. Liao, F.; Hori, Y.; Hudry, E.; Bauer, A.Q.; Jiang, H.; Mahan, T.E.; Lefton, K.B.; Zhang, T.J.; Dearborn, J.T.; Kim, J.; Culver, J.P.; Betensky, R.; Wozniak, D.F.; Hyman, B.T.; Holtzman, D.M., Anti-ApoE antibody given after plaque onset decreases Abeta accumulation and improves brain function in a mouse model of Abeta amyloidosis. J Neurosci, 2014, 34, (21), 7281-7292.
88. Utermann, G.; Langenbeck, U.; Beisiegel, U.; Weber, W., Genetics of the apolipoprotein E system in man. Am J Hum Genet, 1980, 32, (3), 339-347.
89. Poirier, J., Apolipoprotein E represents a potent gene-based therapeutic target for the treatment of sporadic Alzheimer’s disease. Alzheimers Dement, 2008, 4, (1 Suppl 1), S91-97.
90. Vitek, M.P.; Christensen, D.J.; Wilcock, D.; Davis, J.; Van Nostrand, W.E.; Li, F.Q.; Colton, C.A., APOE-mimetic peptides reduce behavioral deficits, plaques and tangles in Alzheimer’s disease transgenics. Neurodegener Dis, 2012, 10, (1-4), 122-126.
91. Laskowitz, D.T.; Song, P.; Wang, H.; Mace, B.; Sullivan, P.M.; Vitek, M.P.; Dawson, H.N., Traumatic brain injury exacerbates neurodegenerative pathology: improvement with an apolipoprotein E-based therapeutic. J Neurotrauma, 2010, 27, (11), 1983-1995.
92. Cramer, P.E.; Cirrito, J.R.; Wesson, D.W.; Lee, C.Y.; Karlo, J.C.; Zinn, A.E.; Casali, B.T.; Restivo, J.L.; Goebel, W.D.; James, M.J.; Brunden, K.R.; Wilson, D.A.; Landreth, G.E., ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science, 2012, 335, (6075), 1503-1506.
93. Hu, J.; Liu, C.C.; Chen, X.F.; Zhang, Y.W.; Xu, H.; Bu, G., Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Abeta metabolism in apoE4-targeted replacement mice. Mol Neurodegener, 2015, 10, (1), 6.
94. Fukumoto, H.; Deng, A.; Irizarry, M.C.; Fitzgerald, M.L.; Rebeck, G.W., Induction of the cholesterol transporter ABCA1 in central nervous system cells by liver X receptor agonists increases secreted Abeta levels. J Biol Chem, 2002, 277, (50), 48508-48513.
95. Wollmer, M.A.; Streffer, J.R.; Lutjohann, D.; Tsolaki, M.; Iakovidou, V.; Hegi, T.; Pasch, T.; Jung, H.H.; Bergmann, K.; Nitsch, R.M.; Hock, C.; Papassotiropoulos, A., ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer’s disease. Neurobiol Aging, 2003, 24, (3), 421-426.
96. Sun, Y.; Yao, J.; Kim, T.W.; Tall, A.R., Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. J Biol Chem, 2003, 278, (30), 27688-27694.
97. Koldamova, R.P.; Lefterov, I.M.; Ikonomovic, M.D.; Skoko, J.; Lefterov, P.I.; Isanski, B.A.; DeKosky, S.T.; Lazo, J.S., 22Rhydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J Biol Chem, 2003, 278, (15), 13244-13256.
98. Karasinska, J.M.; Rinninger, F.; Lutjohann, D.; Ruddle, P.; Franciosi, S.; Kruit, J.K.; Singaraja, R.R.; Hirsch-Reinshagen, V.; Fan, J.; Brunham, L.R.; Bissada, N.; Ramakrishnan, R.; Wellington, C.L.; Parks, J.S.; Hayden, M.R., Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function. J Neurosci, 2009, 29, (11), 3579-3589.
99. Koldamova, R.; Fitz, N.F.; Lefterov, I., ATP-binding cassette transporter A1: from metabolism to neurodegeneration. Neurobiol Dis, 2014, 72 Pt A, 13-21.
100. Koldamova, R.; Staufenbiel, M.; Lefterov, I., Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem, 2005, 280, (52), 43224-43235.
101. Lefterov, I.; Fitz, N.F.; Cronican, A.; Lefterov, P.; Staufenbiel, M.; Koldamova, R., Memory deficits in APP23/Abca1+/-mice correlate with the level of Abeta oligomers. ASN Neuro, 2009, 1, (2).
102. Fitz, N.F.; Cronican, A.A.; Saleem, M.; Fauq, A.H.; Chapman, R.; Lefterov, I.; Koldamova, R., Abca1 deficiency affects Alzheimer’s disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice. J Neurosci, 2012, 32, (38), 13125-13136.
103. Wahrle, S.E.; Jiang, H.; Parsadanian, M.; Kim, J.; Li, A.; Knoten, A.; Jain, S.; Hirsch-Reinshagen, V.; Wellington, C.L.; Bales, K.R.; Paul, S.M.; Holtzman, D.M., Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest, 2008, 118, (2), 671-682.
104. Mandrekar-Colucci, S.; Landreth, G.E., Nuclear receptors as therapeutic targets for Alzheimer’s disease. Expert Opin Ther Targets, 2011, 15, (9), 1085-1097.
105. Costet, P.; Luo, Y.; Wang, N.; Tall, A.R., Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem, 2000, 275, (36), 28240-28245.
106. Kolovou, G.D.; Mikhailidis, D.P.; Anagnostopoulou, K.K.; Daskalopoulou, S.S.; Cokkinos, D.V., Tangier disease four decades of research: a reflection of the importance of HDL. Curr Med Chem, 2006, 13, (7), 771-782.
107. Donkin, J.J.; Stukas, S.; Hirsch-Reinshagen, V.; Namjoshi, D.; Wilkinson, A.; May, S.; Chan, J.; Fan, J.; Collins, J.; Wellington, C.L., ATP-binding cassette transporter A1 mediates the beneficial effects of the liver-X-receptor agonist GW3965 on object recognition memory and amyloid burden in APP/PS1 mice. The Journal of biological chemistry.
108. Koldamova, R.P.; Lefterov, I.M.; Staufenbiel, M.; Wolfe, D.; Huang, S.; Glorioso, J.C.; Walter, M.; Roth, M.G.; Lazo, J.S., The Liver X Receptor Ligand T0901317 Decreases Amyloid {beta} Production in Vitro and in a Mouse Model of Alzheimer’s Disease. J Biol Chem, 2005, 280, (6), 4079-4088.
109. Zelcer, N.; Khanlou, N.; Clare, R.; Jiang, Q.; Reed-Geaghan, E.G.; Landreth, G.E.; Vinters, H.V.; Tontonoz, P., Attenuation of neuroinflammation and Alzheimer’s disease pathology by liver x receptors. Proc Natl Acad Sci U S A, 2007, 104, (25), 10601-10606.
110. Skerrett, R.; Malm, T.; Landreth, G., Nuclear receptors in neurodegenerative diseases. Neurobiol Dis, 2014, 72PA, 104-116.
111. Combs, C.K.; Johnson, D.E.; Karlo, J.C.; Cannady, S.B.; Landreth, G.E., Inflammatory mechanisms in Alzheimer’s disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci, 2000, 20, (2), 558-567.
112. Combs, C.K.; Bates, P.; Karlo, J.C.; Landreth, G.E., Regulation of beta-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor alpha. Neurochem Int, 2001, 39, (5-6), 449-457.
113. Sastre, M.; Dewachter, I.; Rossner, S.; Bogdanovic, N.; Rosen, E.; Borghgraef, P.; Evert, B.O.; Dumitrescu-Ozimek, L.; Thal, D.R.; Landreth, G.; Walter, J.; Klockgether, T.; van Leuven, F.; Heneka, M.T., Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A, 2006, 103, (2), 443-448.
114. Heneka, M.T.; Sastre, M.; Dumitrescu-Ozimek, L.; Hanke, A.; Dewachter, I.; Kuiperi, C.; O’Banion, K.; Klockgether, T.; Van Leuven, F.; Landreth, G.E., Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain, 2005, 128, (Pt 6), 1442-1453.
115. de la Monte, S.M.; Tong, M.; Lester-Coll, N.; Plater, M., Jr.; Wands, J.R., Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer’s disease. J Alzheimers Dis, 2006, 10, (1), 89-109.
116. Kalinin, S.; Richardson, J.C.; Feinstein, D.L., A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer’s disease. Curr Alzheimer Res, 2009, 6, (5), 431-437.
117. Veeraraghavalu, K.; Zhang, C.; Miller, S.; Hefendehl, J.K.; Rajapaksha, T.W.; Ulrich, J.; Jucker, M.; Holtzman, D.M.; Tanzi, R.E.; Vassar, R.; Sisodia, S.S., Comment on “ApoE-Directed Therapeutics Rapidly Clear beta-Amyloid and Reverse Deficits in AD Mouse Models”. Science, 2013, 340, (6135), 924.
118. Tesseur, I.; Lo, A.C.; Roberfroid, A.; Dietvorst, S.; Van Broeck, B.; Borgers, M.; Gijsen, H.; Moechars, D.; Mercken, M.; Kemp, J.; D’Hooge, R.; De Strooper, B., Comment on “ApoE-Directed Therapeutics Rapidly Clear beta-Amyloid and Reverse Deficits in AD Mouse Models”. Science, 2013, 340, (6135), 924.
119. Price, A.R.; Xu, G.; Siemienski, Z.B.; Smithson, L.A.; Borchelt, D.R.; Golde, T.E.; Felsenstein, K.M., Comment on “ApoEDirected Therapeutics Rapidly Clear beta-Amyloid and Reverse Deficits in AD Mouse Models”. Science, 2013, 340, (6135), 924.
120. Fitz, N.F.; Cronican, A.A.; Lefterov, I.; Koldamova, R., Comment on “ApoE-Directed Therapeutics Rapidly Clear beta-Amyloid and Reverse Deficits in AD Mouse Models”. Science, 2013, 340, (6135), 924.
121. Savage, J.C.; Jay, T.; Goduni, E.; Quigley, C.; Mariani, M.M.; Malm, T.; Ransohoff, R.M.; Lamb, B.T.; Landreth, G.E., Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer’s disease. J Neurosci, 2015, 35, (16), 6532-6543.
122. LaClair, K.D.; Manaye, K.F.; Lee, D.L.; Allard, J.S.; Savonenko, A.V.; Troncoso, J.C.; Wong, P.C., Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice. Mol Neurodegener, 2013, 8, 18.
123. Tachibana, M.; Shinohara, M.; Yamazaki, Y.; Liu, C.C.; Rogers, J.; Bu, G.; Kanekiyo, T., Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1. Exp Neurol, 2015, 277, 1-9.
124. Mounier, A.; Georgiev, D.; Nam, K.N.; Fitz, N.F.; Castranio, E.L.; Wolfe, C.M.; Cronican, A.A.; Schug, J.; Lefterov, I.; Koldamova, R., Bexarotene-Activated Retinoid X Receptors Regulate Neuronal Differentiation and Dendritic Complexity. J Neurosci, 2015, 35, (34), 11862-11876.
125. Cummings, J.L.; Zhong, K.; Kinney, J.W.; Heaney, C.; Moll-Tudla, J.; Joshi, A.; Pontecorvo, M.; Devous, M.; Tang, A.; Bena, J., Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease. Alzheimers Res Ther, 2016, 8, (1), 4.
126. Chen, L.; Wang, Y.; Zhang, J.; Hao, L.; Guo, H.; Lou, H.; Zhang, D., Bexarotene nanocrystal-Oral and parenteral formulation development, characterization and pharmacokinetic evaluation. Eur J Pharm Biopharm, 2014, 87, (1), 160-169.
127. Landreth, G.E.; Cramer, P.E.; Lakner, M.M.; Cirrito, J.R.; Wesson, D.W.; Brunden, K.R.; Wilson, D.A., Response to comments on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”. Science, 2013, 340, (6135), 924-g.
128. Duvic, M.; Martin, A.G.; Kim, Y.; Olsen, E.; Wood, G.S.; Crowley, C.A.; Yocum, R.C.; Worldwide Bexarotene Study, G., Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol, 2001, 137, (5), 581-593.
129. Miller, V.A.; Benedetti, F.M.; Rigas, J.R.; Verret, A.L.; Pfister, D.G.; Straus, D.; Kris, M.G.; Crisp, M.; Heyman, R.; Loewen, G.R.; Truglia, J.A.; Warrell, R.P., Jr., Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol, 1997, 15, (2), 790-795.
130. Lowe, M.N.; Plosker, G.L., Bexarotene. Am J Clin Dermatol, 2000, 1, (4), 245-250; discussion 251-242.
131. Zhang, C.; Duvic, M., Treatment of cutaneous T-cell lymphoma with retinoids. Dermatol Ther, 2006, 19, (5), 264-271.
132. Dawson, M.I.; Xia, Z., The retinoid X receptors and their ligands. Biochim Biophys Acta, 2012, 1821, (1), 21-56.
133. Torino, F.; Barnabei, A.; Paragliola, R.; Baldelli, R.; Appetecchia, M.; Corsello, S.M., Thyroid dysfunction as an unintended side effect of anticancer drugs. Thyroid, 2013, 23, (11), 1345-1366.
134. Duvic, M.; Hymes, K.; Heald, P.; Breneman, D.; Martin, A.G.; Myskowski, P.; Crowley, C.; Yocum, R.C.; Bexarotene Worldwide Study, G., Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol, 2001, 19, (9), 2456-2471.
135. Evans, R.M.; Mangelsdorf, D.J., Nuclear Receptors, RXR, and the Big Bang. Cell, 2014, 157, (1), 255-266.
136. de la Monte, S.M., Relationships between diabetes and cognitive impairment. Endocrinol Metab Clin North Am, 2014, 43, (1), 245-267.
137. Weissenborn, K.; Bokemeyer, M.; Krause, J.; Ennen, J.; Ahl, B., Neurological and neuropsychiatric syndromes associated with liver disease. AIDS, 2005, 19 Suppl 3, S93-98.
138. Lewis, M.; Howdle, P.D., The neurology of liver failure. QJM, 2003, 96, (9), 623-633.
139. Zafari, S.; Backes, C.; Meese, E.; Keller, A., Circulating Biomarker Panels in Alzheimer’s Disease. Gerontology, 2015, 61, (6), 497-503.
140. Blennow, K.; Hampel, H.; Weiner, M.; Zetterberg, H., Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol, 2010, 6, (3), 131-144.
141. Zhao, Y.; Bhattacharjee, S.; Dua, P.; Alexandrov, P.N.; Lukiw, W.J., MicroRNA-Based Biomarkers and the Diagnosis of Alzheimer’s Disease. Front Neurol, 2015, 6, 162.
142. Skerrett, R.; Pellegrino, M.P.; Casali, B.T.; Taraboanta, L.; Landreth, G.E., Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor gamma Agonist Treatment Reduces Amyloid beta Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice. J Biol Chem, 2015, 290, (35), 21591-21602.
143. Casali, B.T.; Corona, A.W.; Mariani, M.M.; Karlo, J.C.; Ghosal, K.; Landreth, G.E., Omega-3 Fatty Acids Augment the Actions of Nuclear Receptor Agonists in a Mouse Model of Alzheimer’s Disease. J Neurosci, 2015, 35, (24), 9173-9181.
144. Kremoser, C.; Albers, M.; Burris, T.P.; Deuschle, U.; Koegl, M., Panning for SNuRMs: using cofactor profiling for the rational discovery of selective nuclear receptor modulators. Drug Discov Today, 2007, 12, (19-20), 860-869.
145. Marshall, P.A.; Jurutka, P.W.; Wagner, C.E.; van der Vaart, A.; Kaneko, I.; Chavez, P.I.; Ma, N.; Bhogal, J.S.; Shahani, P.; Swierski, J.C.; MacNeill, M., Analysis of differential secondary effects of novel rexinoids: select rexinoid X receptor ligands demonstrate differentiated side effect profiles. Pharmacol Res Perspect, 2015, 3, (2), e00122.
146. Perez, E.; Bourguet, W.; Gronemeyer, H.; de Lera, A.R., Modulation of RXR function through ligand design. Biochim Biophys Acta, 2012, 1821, (1), 57-69.
147. Vaz, B.; de Lera, A.R., Advances in drug design with RXR modulators. Expert Opin Drug Discov, 2012, 7, (11), 1003-1016.
148. Hafiane, A.; Bielicki, J.K.; Johansson, J.O.; Genest, J., Novel Apo E-Derived ABCA1 Agonist Peptide (CS-6253) Promotes Reverse Cholesterol Transport and Induces Formation of prebeta-1 HDL In Vitro. PLoS One, 2015, 10, (7), e0131997.
149. Laskowitz, D.T.; Fillit, H.; Yeung, N.; Toku, K.; Vitek, M.P., Apolipoprotein E-derived peptides reduce CNS inflammation: implications for therapy of neurological disease. Acta Neurol Scand Suppl, 2006, 185, 15-20.
150. Watson, G.S.; Cholerton, B.A.; Reger, M.A.; Baker, L.D.; Plymate, S.R.; Asthana, S.; Fishel, M.A.; Kulstad, J.J.; Green, P.S.; Cook, D.G.; Kahn, S.E.; Keeling, M.L.; Craft, S., Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. The American journal of geriatric psychiatry, 2005, 13, (11), 950-958.
151. Sato, T.; Hanyu, H.; Hirao, K.; Kanetaka, H.; Sakurai, H.; Iwamoto, T., Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging, 2011, 32, (9), 1626-1633.
152. Gao, M.; Bu, L.; Ma, Y.; Liu, D., Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice. PLoS One, 2013, 8, (6), e65641.
153. Hong, C.; Tontonoz, P., Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov, 2014, 13, (6), 433-444.
154. Janowski, B.A., The hypocholesterolemic agent LY295427 upregulates INSIG-1, identifying the INSIG-1 protein as a mediator of cholesterol homeostasis through SREBP. Proc Natl Acad Sci U S A, 2002, 99, (20), 12675-12680.
155. Corona, A.W.; Kodoma, N.; Casali, B.T.; Landreth, G.E., ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice. J Neuroimmune Pharmacol, 2015.
156. O’Hare, E.; Jeggo, R.; Kim, E.M.; Barbour, B.; Walczak, J.S.; Palmer, P.; Lyons, T.; Page, D.; Hanna, D.; Meara, J.R.; Spanswick, D.; Guo, J.P.; McGeer, E.G.; McGeer, P.L.; Hobson, P., Lack of support for bexarotene as a treatment for Alzheimer’s disease. Neuropharmacology, 2016, 100, 124-130.
157. Boettcher, E.; Csako, G.; Pucino, F.; Wesley, R.; Loomba, R., Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther, 2012, 35, (1), 66-75.
158. Lee, M.Y.; Choi, R.; Kim, H.M.; Cho, E.J.; Kim, B.H.; Choi, Y.S.; Naowaboot, J.; Lee, E.Y.; Yang, Y.C.; Shin, J.Y.; Shin, Y.G.; Chung, C.H., Peroxisome proliferator-activated receptor delta agonist attenuates hepatic steatosis by anti-inflammatory mechanism. Exp Mol Med, 2012, 44, (10), 578-585.
159. Yang, S.J.; Choi, J.M.; Chae, S.W.; Kim, W.J.; Park, S.E.; Rhee, E.J.; Lee, W.Y.; Oh, K.W.; Park, S.W.; Kim, S.W.; Park, C.Y., Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats. PLoS One, 2011, 6, (2), e17057.
160. Nan, Y.M.; Fu, N.; Wu, W.J.; Liang, B.L.; Wang, R.Q.; Zhao, S.X.; Zhao, J.M.; Yu, J., Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. Scand J Gastroenterol, 2009, 44, (3), 358-365.
161. Mandrekar-Colucci, S.; Karlo, J.C.; Landreth, G.E., Mechanisms underlying the rapid peroxisome proliferator-activated receptorgamma-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer’s disease. J Neurosci, 2012, 32, (30), 10117-10128.
162. Grefhorst, A.; Elzinga, B.M.; Voshol, P.J.; Plosch, T.; Kok, T.; Bloks, V.W.; van der Sluijs, F.H.; Havekes, L.M.; Romijn, J.A.; Verkade, H.J.; Kuipers, F., Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem, 2002, 277, (37), 34182-34190.
163. Schultz, J.R.; Tu, H.; Luk, A.; Repa, J.J.; Medina, J.C.; Li, L.; Schwendner, S.; Wang, S.; Thoolen, M.; Mangelsdorf, D.J.; Lustig, K.D.; Shan, B., Role of LXRs in control of lipogenesis. Genes Dev, 2000, 14, (22), 2831-2838.
164. Lenhard, J.M.; Lancaster, M.E.; Paulik, M.A.; Weiel, J.E.; Binz, J.G.; Sundseth, S.S.; Gaskill, B.A.; Lightfoot, R.M.; Brown, H.R., The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction. Diabetologia, 1999, 42, (5), 545-554.
165. Goncalves, M.B.; Clarke, E.; Hobbs, C.; Malmqvist, T.; Deacon, R.; Jack, J.; Corcoran, J.P., Amyloid beta inhibits retinoic acid synthesis exacerbating Alzheimer disease pathology which can be attenuated by an retinoic acid receptor alpha agonist. Eur J Neurosci, 2013, 37, (7), 1182-1192.